Morgan Stanley Terns Pharmaceuticals, Inc. Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Morgan Stanley holds 7,110,105 shares of TERN stock, worth $25.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,110,105

Previous 3,347,807 112.38%

Holding current value

$25.3 Million

Previous $18.7 Million 5.05%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$2.76 - $5.79 $10.4 Million - $21.8 Million	3,762,298 Added 112.38%	7,110,105 $19.6 Million
Q4 2024 Feb 14, 2025	BUY	$5.53 - $8.36 $14.2 Million - $21.4 Million	2,564,875 Added 327.6%	3,347,807 $18.7 Million
Q3 2024 May 14, 2025	BUY	$6.49 - $10.8 $2.92 Million - $4.85 Million	449,314 Added 134.68%	782,932 $6.53 Million
Q3 2024 Nov 14, 2024	BUY	$6.49 - $10.8 $2.92 Million - $4.85 Million	449,314 Added 134.68%	782,932 $6.53 Million
Q2 2024 May 14, 2025	SELL	$4.54 - $8.2 $13.7 Million - $24.7 Million	-3,014,189 Reduced 90.03%	333,618 $2.27 Million
Q2 2024 Oct 17, 2024	SELL	$4.54 - $8.2 $1.15 Million - $2.08 Million	-253,175 Reduced 43.15%	333,618 $2.27 Million
Q2 2024 Aug 14, 2024	SELL	$4.54 - $8.2 $1.15 Million - $2.08 Million	-253,175 Reduced 43.15%	333,618 $2.27 Million
Q1 2024 Oct 17, 2024	BUY	$4.86 - $8.19 $1.23 Million - $2.07 Million	253,175 Added 75.89%	586,793 $3.85 Million
Q1 2024 Aug 16, 2024	SELL	$4.86 - $8.19 $5.53 Million - $9.32 Million	-1,137,913 Reduced 65.98%	586,793 $3.85 Million
Q1 2024 May 15, 2024	SELL	$4.86 - $8.19 $5.53 Million - $9.32 Million	-1,137,913 Reduced 65.98%	586,793 $3.85 Million
Q4 2023 Aug 16, 2024	BUY	$3.37 - $6.86 $4.69 Million - $9.54 Million	1,391,088 Added 416.97%	1,724,706 $11.2 Million
Q4 2023 Feb 13, 2024	BUY	$3.37 - $6.86 $2.45 Million - $4.99 Million	726,946 Added 72.86%	1,724,706 $11.2 Million
Q3 2023 Nov 15, 2023	BUY	$4.7 - $8.55 $4.03 Million - $7.34 Million	858,170 Added 614.78%	997,760 $5.02 Million
Q2 2023 Aug 14, 2023	SELL	$7.35 - $13.29 $17,243 - $31,178	-2,346 Reduced 1.65%	139,590 $1.22 Million
Q1 2023 May 15, 2023	BUY	$7.91 - $12.0 $979,874 - $1.49 Million	123,878 Added 686.0%	141,936 $1.68 Million
Q4 2022 Feb 14, 2023	BUY	$4.62 - $10.18 $49,965 - $110,096	10,815 Added 149.32%	18,058 $183,000
Q3 2022 Nov 14, 2022	SELL	$1.87 - $6.42 $21,370 - $73,367	-11,428 Reduced 61.21%	7,243 $42,000
Q2 2022 Oct 27, 2022	BUY	$1.5 - $3.0 $15,270 - $30,540	10,180 Added 119.89%	18,671 $46,000
Q2 2022 Aug 15, 2022	BUY	$1.5 - $3.0 $15,270 - $30,540	10,180 Added 119.89%	18,671 $46,000
Q1 2022 Oct 27, 2022	SELL	$2.83 - $6.7 $28,809 - $68,206	-10,180 Reduced 54.52%	8,491 $25,000
Q1 2022 May 13, 2022	SELL	$2.83 - $6.7 $229,130 - $542,465	-80,965 Reduced 90.51%	8,491 $25,000
Q4 2021 Feb 14, 2022	BUY	$5.65 - $10.73 $358,277 - $680,410	63,412 Added 243.48%	89,456 $632,000
Q3 2021 Nov 15, 2021	BUY	$7.22 - $13.46 $188,037 - $350,552	26,044 New	26,044 $271,000

Others Institutions Holding TERN

# of Institutions

143

Shares Held

84.5M

Call Options Held

256K

Put Options Held

133K

View Full List

About Terns Pharmaceuticals, Inc.

Ticker TERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,613,800
Market Cap $134M
Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...

More about TERN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account